Summit Therapeutics Inc (SMMT)

Summit Therapeutics' stock price has been impacted by several key events in the past six months. On May 1, 2026, the stock price was $16.11, with a 52-week range between $13.83 and $30.98. The stock experienced a significant drop of 24.91% following the release of its first-quarter financial results due to widening non-GAAP net losses, rising expenses, and a lack of immediate clinical catalysts. Analysts have adjusted price targets, with H.C. Wainwright lowering its target to $23 from $30 in early May 2026. Despite recent declines, the stock has shown a strong multi-year return.

Summit Therapeutics, as a biopharmaceutical company focused on drug development, does not experience direct demand seasonality for commercialized products. The company's revenue and progress are tied to clinical trial milestones, regulatory approvals, and R&D spending. Analysis of historical stock price data suggests some seasonality in stock performance, with a 40% probability of a positive return in May and a 60% probability in July, reflecting potential investor sentiment or market trends.

Summit Therapeutics is a biopharmaceutical oncology company focused on discovering, developing, and commercializing therapies to improve the lives of patients with unmet medical needs. Their lead candidate, ivonescimab, is a bispecific antibody in Phase III trials for NSCLC and CRC. They also have ridinilazole, an oral antibiotic for CDI, in Phase III trials.

Summit Therapeutics is headquartered in Miami, Florida, with additional offices in Palo Alto, California; Princeton, New Jersey; Oxford, United Kingdom; and Dublin, Ireland. They hold rights to ivonescimab in North America, South America, Europe, the Middle East, Africa, and Japan, while Akeso Inc. retains rights for other territories, including China. For ridinilazole, Summit Therapeutics has geographical segments in the United States and the United Kingdom.

Summit Therapeutics has achieved "Great Place to Work® Certification™," indicating a positive internal reputation. The recent stock price decline due to clinical trial updates and financial results could indirectly affect investor confidence and perception.

Summit Therapeutics has a significant institutional and individual ownership presence. As of May 5, 2026, 223 institutional owners and shareholders held a total of 117,511,694 shares. Major institutional shareholders include Baker Bros. Advisors Lp, Fmr Llc, Vanguard Group Inc, Price T Rowe Associates Inc /md/, BlackRock, Inc., State Street Corp, Geode Capital Management, Llc, Citadel Advisors Llc, and Susquehanna International Group, Llp. Insider ownership is also substantial, with Mahkam Zanganeh owning 82.61% of the company's shares and Robert W. Duggan owning 78.17%.